60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP

60 Degrees Pharmaceuticals — H.C. Wainwright Presentation, September 2025

24 slides from 60 Degrees Pharmaceuticals's conference presentation, Sep 9, 2025

1. Slide 1: H.C. Wainwright Presentation, September 2025

   ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. September 2025 H.C. Wainwright Presentation

2. Slide 2: Disclaimer and Forward-looking Statements

   Disclaimer and Forward - looking Statements ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the “Company”) and d

3. Slide 3: Market Cap: $5.8 million

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Market Cap: $5.8 million

4. Slide 4: Use of ARAKODA for Chronic Babesiosis Is Increasing Sales

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 0 20000 40000 60000 80000 100000 120000 140000 160000 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 9/2019 8/2025 PANDEMIC SUPPLY CHAIN DISRUPTION PATIENT BABESIOSIS CALL

5. Slide 5: Gross Margins Look Good, So Our Focus is on Increasing Sales

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Gross Margins Look Good, So Our Focus is on Increasing Sales Q2 25 Q1 25 Q4 24 Q3 24 Q2 24 Q1 24 Q4 23 Q3 23 1,082 1,579 1,477 1,319 1,301 1,022 566 550 US Pharmacy Deliveries (16 ct box) 101 164 231 135 125 116 126 51 Net Reve

6. Slide 6: Future Sales of Arakoda Could Increase by Orders of Magnitude

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 0 50 100 150 200 250 Annualized Sales Now Max Potential Sales (2035) Future Sales of Arakoda Could Increase by Orders of Magnitude* *Assuming company market research is accurate and FDA approval of Arakoda is achieved

7. Slide 7: Future Arakoda Sales for Chronic Babesiosis Could Be Higher Than Malaria

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Malaria Prevention Chronic Babesiosis Other Babesiosis Future Arakoda Sales for Chronic Babesiosis Could be Higher Than Malaria* *Based on internal market research that assumes FDA approval Arakoda for treatment of babesiosis

8. Slide 8: reserved. Roberts wrote, “Malaria is an awful disease that needs to be attacked full

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Roberts wrote, “Malaria is an awful disease that needs to be attacked full - force when a diagnosis is made. In my time here, I’ve gone from being so sick that any dog would take pity on me to being ready to fire up the grill o

9. Slide 9: Malaria in Travelers is Increasing Because They Don't Take Their Meds

   ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Malaria in Travelers is Increasing Because They Don’t Take Their Meds No vaccines 95% of cases in people who don’t take their meds • References: 1. Mace KE, et al. MMWR Surveill Summ . 2022;71(8):1 - 35. 2. Centers for Disease

10. Slide 10: Selecting The Correct Antimalarial Prophylaxis is Complicated!

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Selecting The Correct Antimalarial Prophylaxis is Complicated! P. vivax (relapses post travel) P. falciparum (deadly but does not relapse) Very little P. vivax malaria in Africa From MAP Project

11. Slide 11: ARAKODA Has a Lower Pill Burden

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. ARAKODA Has a Lower Pill Burden* Standard of care Atovaquone/proguanil/primaquine 53 pills ARAKODA 16 pills *For one month trip

12. Slide 12: Arakoda Market Research Revealed Some Challenges to Solve

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. A rakoda Market Research Revealed Some Challenges to Solve Brand recognition is low HCPs and patients liked product profile Generic alternatives have lower out of pocket costs G6PD testing requirement a potential barrier for so

13. Slide 13: Commercial Pilot for Malaria Indication Addresses Barriers to Use

    Commercial Pilot for Malaria Indication Addresses Barriers to Use Increase Awareness and Differentiate ARAKODA Differentiate ARAKODA from the generic competition with a clear and compelling value story Drive ARAKODA Trial & Usage Encourage HCPS to prescribe ARAKODA for appropriate patients based on

14. Slide 14: Babesiosis is a Parasite Transmitted By Ticks and Blood Donation

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Babesiosis is a Parasite Transmitted By Ticks and Blood Donation • Reference: 1. Centers for Disease Control. Babesiosis. 2017. www.cdc.gov/dpdx/babesiosis/index.html

15. Slide 15: Blood Donation Screening Decreases Babesia Transmission, Revealing Hidden Reservoir

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Blood Donation Screening Decreases Babesia Transmission, Revealing Hidden Resevoir of Viable Parasites Observation: Blood donors usually do not donate blood if they are feeling sick and would likely not know they had a Babesia

16. Slide 16: Conventional Treatments Resolve Symptoms, But Unclear if Parasite Reservoirs Eliminated

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Lower Limit of Analytical Sensitivity (parasites/mL) Target Diagnostic Method(s) 100,000 Whole organisms Microscopy 1,540 18s RNA probe (DNA) Real Time PCR (e.g. Mayo) 3 RNA Blood Bank Test (transcription amplified) Observation

17. Slide 17: Clinical Significance of Residual Parasite Burden: Main-Stream Perspective

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Clinical Significance of Residual Parasite Burden: Main - Stream Perspective Immunocompetent person Immunosuppressed person Infection clears Infection clears, but becomes sick again Person with no spleen

18. Slide 18: Chronic Babesiosis is a Problem: Prescribing Physician Perspective

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Chronic Babesiosis is a Problem: Prescribing Physician Perspective Dr. Richard Horowitz: “Chronic Babesiosis is seen in the vast majority of my chronically ill patients with Lyme disease. Present regimens with Mepron and Zithro

19. Slide 19: Tafenoquine Kills Babesia and Malaria Parasites the Same Way, at Similar Doses

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tafenoquine Kills Babesia and Malaria Parasites the Same Way, at Similar Doses Tafenoquine kills Babesia and Malaria parasites in the same way Similar doses clear both infections in animal models Giemsa - stained blood smears o

20. Slide 20: Tafenoquine Had an 80% Cure Rate in 5 Immunosuppressed Babesiosis Patients

    ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Tafenoquine Had an 80% Cure Rate in 5 Immunosuppressed Babesiosis Patients With Weekly Dosing Plus Standard of Care 1 Representative Case 1. Krause PJ, et al. Clin Infect Dis. doi:10.1093/ cid /ciae238

21. Slide 21: Research Strategy Focused on FDA Approval and Broadening Acceptance

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Demonstrate statistical significance in at least one clinical trial Research Strategy Focused on FDA Approval and Broadening Acceptance Tidy up Prove that chronic babesiosis can be diagnostically confirmed Schedule meeting with

22. Slide 22: Three Clinical Trials of Arakoda Will Confirm Efficacy Against Babesiosis

    ©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. Three Clinical Trials of Arakoda Will Confirm Efficacy Against Babesiosis and That Chronic Babesiosis Is Associated With Persistent Infection* Initial Enrolment Complete Number Enrolled Min/Max Sample Size Type Population Combi

23. Slide 23: NCT06656351 Will Prove Chronic Babesiosis is Due to Persistent Infection

    ©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. NCT96656351 Will Prove Chronic Babesiosis is Due to Persistent Infection* A Phase II Open Label Study of Tafenoquine in Chronic Babesiosis Patients Patients (key inclusions) Severe disabling fatigue with substantial functional

24. Slide 24: Achieving Key Milestones Will Derisk Business Plan in 2025-2026

    Achieving Key Milestones Will Derisk Business Plan in 2025 - 2026 Q1 2025 Q2 2025 Q3 /4 2025 Q4 2025 Earliest Q 4 / 202 5 No earlier than Q2 2026 140% YOY Revenue Growth Recruitment Status of Babesia Trial(s) Market Research and Epidemiologic Outputs for Babesiosis Sales Outputs From ARAKODA Commerc

60 Degrees Pharmaceuticals — H.C. Wainwright Presentation, September 2025 on 6ix